Wescott Financial Advisory Group LLC purchased a new stake in shares of Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) in the second quarter, HoldingsChannel.com reports. The fund purchased 20,486 shares of the specialty pharmaceutical company’s stock, valued at approximately $29,000.
Other hedge funds also recently bought and sold shares of the company. Schonfeld Strategic Advisors LLC lifted its position in shares of Ampio Pharmaceuticals by 121.6% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 34,638 shares of the specialty pharmaceutical company’s stock valued at $58,000 after acquiring an additional 19,010 shares during the period. Barclays PLC purchased a new position in shares of Ampio Pharmaceuticals during the 1st quarter worth approximately $46,000. Brookstone Capital Management purchased a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $33,000. Woodward Diversified Capital LLC increased its stake in shares of Ampio Pharmaceuticals by 331.5% during the 2nd quarter. Woodward Diversified Capital LLC now owns 19,500 shares of the specialty pharmaceutical company’s stock worth $33,000 after purchasing an additional 14,981 shares in the last quarter. Finally, SRS Capital Advisors Inc. purchased a new position in shares of Ampio Pharmaceuticals during the 2nd quarter worth approximately $1,051,000. Institutional investors own 22.53% of the company’s stock.
Separately, Zacks Investment Research cut shares of Ampio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, July 5th.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) last issued its quarterly earnings data on Tuesday, August 3rd. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.02). As a group, research analysts anticipate that Ampio Pharmaceuticals, Inc. will post -0.08 EPS for the current fiscal year.
In other Ampio Pharmaceuticals news, CFO Dan Stokely sold 22,500 shares of Ampio Pharmaceuticals stock in a transaction that occurred on Friday, June 25th. The shares were sold at an average price of $1.79, for a total value of $40,275.00. Following the completion of the sale, the chief financial officer now directly owns 50,815 shares of the company’s stock, valued at approximately $90,958.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.59% of the stock is currently owned by insiders.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.
Want to see what other hedge funds are holding AMPE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE).
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.